Bruker Scientific Sponsored Presentation: MBT Sepsityper® - When Every Minute Counts
In this presentation, Dr. Kostrzewa will introduce Bruker’s most recent innovation, the MBT Sepsityper Kit US IVD, that can directly impact sepsis outcomes for the patient and the treating institution. Currently, guidelines call for physicians to treat septic patients quickly with broad-spectrum antibiotics with the goal of switching to a more targeted therapy once the infecting organisms have been identified and/or any antibiotic resistances have been determined. The newly FDA cleared MBT Sepsityper Kit US IVD can improve this process by providing rapid, and highly accurate, microbial identifications direct from positive blood culture in under 20 minutes to clinical microbiologists and treating physicians. Harvested microorganisms are processed, and then identified using the FDA-cleared MALDI Biotyper CA System, with a reference library that covers 488 different gram-negative and gram-positive bacterial species and groups, including over 90 anaerobes, as well as yeasts, including Candida auris.
Industry leaders, Public Policy Experts, Health and hospital Leadership (C-Suite, physicians, nurses, pharmacists, CIOs), Health quality and decision support leaders, Health Investors and VCs, Health and Technology Media, Health Advocates, Health Advisors, Health Educators, Health Marketers.
Markus Kostrzewa, PhD
SVP Microbiology & Diagnostics Innovations, R&D, Regulatory and Scientific Affairs / Director Bioanalytical Development, Bruker Daltonics
Dr. Markus Kostrzewa joined Bruker in 1998 as Head of the new R&D group “Bioanalytical Development“, establishing molecular biology and biology related development at Bruker Daltonik GmbH. The initial focus went to development of DNA analysis methods by MALDI-TOF mass spectrometry, and “Clinical Proteomics”, the latter covering methods, consumables and software for mass spectrometry profiling of body fluids and tissues. His R&D group progressed to successful development of microorganism identification by Bruker’s MALDI-TOF mass spectrometry, today globally known as the “MALDI Biotyper” system. Dr. Kostrzewa became Director Molecular Biology R&D in 2005, then promoted to Vice President Clinical Mass Spectrometry R&D in 2012, which was broadened to Vice President Microbiology & Diagnostics R&D in 2017. Since 2019, Dr. Kostrzewa is Bruker’s Senior Vice President Microbiology & Diagnostics R&D, Regulatory and Scientific Affairs, heading innovation at Bruker Microbiology and Diagnostics. This includes strategic planning of innovative products and driving regulatory approval processes (IVD-CE labelling, FDA clearance, ISO/AOAC certification for Food market).
No continuing education credits are offered for this session.
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare provider. Sepsis Alliance recommends users consult their physician or healthcare provider regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.